The news roundup for the week ending 16 September 2016.
Big deal: Allergan spots RetroSense for $60m
The acquisition of Wayne State University spinout RetroSense followed a licensing agreement with University of California, San Diego for another compound and may yet exceed $60m.
The university has supported the House Fund, set up by an alumnus, through its UC Ventures initiative.
Novartis enters Inflazome in $17m series A
Novartis has co-led a $17m series A round for Inflazome, which is working on treatments for a range of chronic inflammatory diseases.
All change at Imperial Create Lab
Mark Hammond, Dominic Falcão and Jack Owen have left Imperial Create Lab, and are replaced by Liz Choonara, Lauren Dennis, Nikita Thakrar.
Warwick to incubate in California
The university, which hopes to open a campus in California in 2018, will set up a business development centre at the site modelled on its existing commercialisation arm Warwick Ventures.
Phononic keeps its cool with $30m
Rex Healthcare has returned to back a $30m round for the thermal heating and cooling technology maker, having previously contributed to a $44m series D in 2014.
Flynn resurfaces at Tyton Partners
Rich Flynn, who stepped down from his position as president of Apollo Education Ventures in April, has joined Tyton Partners as managing director.
Phononic keeps its cool with $30m
Rex Healthcare has returned to back a $30m round for the thermal heating and cooling technology maker, having previously contributed to a $44m series D in 2014.
Relay Therapeutics sets itself in motion with $57m
DE Shaw Research has backed a series A round for Relay Therapeutics, launched yesterday to commercialise research from Shaw and a range of universities.
Eyevensys re-inspects series A
Eyevensys, based on reserach conducted at Paris Descartes University, closes its series A round at $10m three years after it raised the initial tranche.
Deal net: 12 – 16 September 2016
The Global University Venturing deal net rounds up all the latest smaller deals and tracks emerging companies accessing government funds.
